Freestone Capital Holdings’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$830K Buy
5,436
+339
+7% +$52K 0.03% 264
2025
Q4
$703K Buy
5,097
+1,834
+56% +$240K 0.02% 290
2025
Q3
$418K Sell
3,263
-5
-0.2% -$610 0.01% 378
2025
Q2
$395K Sell
3,268
-216
-6% -$24.3K 0.01% 329
2025
Q1
$388K Sell
3,484
-266
-7% -$28.3K 0.01% 314
2024
Q4
$365K Sell
3,750
-210
-5% -$22.4K 0.01% 324
2024
Q3
$455K Sell
3,960
-80
-2% -$9.08K 0.02% 306
2024
Q2
$430K Sell
4,040
-348
-8% -$34.9K 0.02% 321
2024
Q1
$424K Sell
4,388
-161
-4% -$16.5K 0.02% 323
2023
Q4
$459K Sell
4,549
-190
-4% -$18.3K 0.02% 284
2023
Q3
$483K Sell
4,739
-2,546
-35% -$258K 0.03% 245
2023
Q2
$735K Sell
7,285
-1,757
-19% -$176K 0.03% 225
2023
Q1
$832K Sell
9,042
-560
-6% -$48.9K 0.04% 212
2022
Q4
$871K Sell
9,602
-11,470
-54% -$966K 0.04% 208
2022
Q3
$1.6M Sell
21,072
-15,655
-43% -$1.3M 0.07% 162
2022
Q2
$3.1M Sell
36,727
-46,229
-56% -$4.06M 0.12% 120
2022
Q1
$7.28M Buy
82,956
+10,834
+15% +$938K 0.29% 76
2021
Q4
$6.31M Sell
72,122
-170
-0.2% -$14.1K 0.27% 79
2021
Q3
$5.91M Sell
72,292
-7,739
-10% -$696K 0.3% 81
2021
Q2
$7.3M Sell
80,031
-2,548
-3% -$227K 0.37% 69
2021
Q1
$7.06M Buy
82,579
+24,947
+43% +$2.24M 0.38% 68
2020
Q4
$5.44M Sell
57,632
-14,034
-20% -$1.23M 0.32% 75
2020
Q3
$6.23M Sell
71,666
-1,319
-2% -$114K 0.41% 58
2020
Q2
$6.38K Buy
72,985
+4,841
+7% +$418K 0.07% 62
2020
Q1
$5.62K Buy
68,144
+25,941
+61% +$2.31M 0.12% 60
2019
Q4
$4K Buy
42,203
+4,540
+12% +$407K 0.08% 111
2019
Q3
$3.27K Buy
37,663
+1,640
+5% +$147K 0.08% 128
2019
Q2
$3.29K Buy
36,023
+3,303
+10% +$280K 0.08% 127
2019
Q1
$2.82M Buy
32,720
+5,763
+21% +$463K 0.17% 142
2018
Q4
$2.07M Buy
26,957
+8,204
+44% +$639K 0.14% 159
2018
Q3
$1.45M Buy
18,753
+2,756
+17% +$204K 0.01% 186
2018
Q2
$1.08M Buy
15,997
+2,188
+16% +$151K 0.01% 217
2018
Q1
$1M Buy
13,809
+280
+2% +$21.3K 0.06% 220
2017
Q4
$1.02M Buy
13,529
+1,076
+9% +$81.2K 0.07% 214
2017
Q3
$958K Buy
12,453
+603
+5% +$45.5K 0.07% 211
2017
Q2
$886K Buy
11,850
+693
+6% +$49.1K 0.07% 204
2017
Q1
$742K Sell
11,157
-198
-2% -$13.2K 0.06% 223
2016
Q4
$741K Sell
11,355
-6,854
-38% -$445K 0.06% 219
2016
Q3
$1.29M Sell
18,209
-574
-3% -$41.8K 0.12% 153
2016
Q2
$1.39M Sell
18,783
-884
-4% -$61.1K 0.14% 142
2016
Q1
$1.28M Sell
19,667
-4,227
-18% -$288K 0.13% 139
2015
Q4
$1.84M Buy
23,894
+7,122
+42% +$566K 0.19% 78
2015
Q3
$1.38M Buy
16,772
+2,023
+14% +$180K 0.15% 123
2015
Q2
$1.3M Sell
14,749
-2,442
-14% -$224K 0.21% 77
2015
Q1
$1.52M Sell
17,191
-13,309
-44% -$1.18M 0.24% 61
2014
Q4
$2.53M Buy
30,500
+109
+0.4% +$9.04K 0.42% 36
2014
Q3
$2.56M Sell
30,391
-1,541
-5% -$125K 0.44% 39
2014
Q2
$2.59M Sell
31,932
-2,657
-8% -$209K 0.4% 47
2014
Q1
$2.63M Sell
34,589
-10,225
-23% -$745K 0.47% 37
2013
Q4
$3.23M Buy
44,814
+262
+0.6% +$18.2K 0.57% 34
2013
Q3
$3.06M Buy
44,552
+2,161
+5% +$143K 0.55% 32
2013
Q2
$2.69M Buy
+42,391
New +$2.76M 0.55% 37

Other funds holding NVS

Freestone Capital Holdings's NVS Position: Q1 2026 in Review

Freestone Capital Holdings increased its Novartis (NVS) stake by 6.7% in Q1 2026, buying an estimated $52K and bringing the position to 5,436 shares worth $830K. The position accounts for 0.03% of the portfolio, ranked #264.

Freestone Capital Holdings first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.3M in Q2 2021. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Freestone Capital Holdings held 5,436 shares of Novartis worth $830K as of Q1 2026.
  • Freestone Capital Holdings bought 339 Novartis shares in Q1 2026, an estimated $52K.
  • Novartis made up 0.03% of Freestone Capital Holdings's portfolio in Q1 2026, its #264 holding.
  • Freestone Capital Holdings first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Freestone Capital Holdings's Novartis position peaked at $7.3M in Q2 2021.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Freestone Capital Holdings's 13F filing for Q1 2026, filed 13 May 2026.